Skip to content
Open access

Targeting TLR4 alleviates the progression of experimental autoimmune encephalomyelitis by regulating central resident cells and Th1/Th17 cell differentiation

Oct 2026 · Frontiers in Immunology · Vol 17 · 0 citations · 38 references
Medicine

TL;DR

Results demonstrate that targeting TLR4 simultaneously curtails pathogenic T-cell differentiation and local neuroinflammation, establishing TLR4 as a dual-action therapeutic target for MS.

Abstract

Multiple sclerosis (MS) is an autoimmune demyelinating disease characterized by neuroinflammation. Toll-like receptor 4 (TLR4) is a receptor for damage-associated molecular patterns, such as high-mobility group box 1 (HMGB1) and plays a role in innate immunity. However, its precise role and cellular dynamics in MS pathogenesis are unclear. Using the experimental autoimmune encephalomyelitis (EAE) model, we mapped the expression dynamics of TLR4 and found that in the spinal cords, the cell type associated with the disease shifted from neurons to activated glia. To establish causality, we subjected TLR4-/- mice to EAE and observed significantly attenuated disease severity, reduced demyelination, and preserved neuronal integrity, alongside suppressed microglial and astrocytic activation. Furthermore, TLR4 deficiency was not merely dampening CNS-localized inflammation but was also associated with suppressed peripheral MOG35–55-specific Th1/Th17 effector responses, as evidenced by reduced production of IFN-γ and IL-17A in lymphoid organs, together with reduced TNF-α, as well as diminished expression of the Th1/Th17 lineage-defining transcription factors T-bet and RORγt in the spinal cord infiltrates. This suggests that TLR4 plays a key role in EAE pathology by connecting peripheral Th1/Th17 differentiation with central glial inflammatory responses. Critically, to translate these findings, we evaluated the small-molecule TLR4 antagonist TAK-242. While prophylactic administration was effective, therapeutic dosing initiated after disease onset still significantly alleviated clinical scores and delayed progression, highlighting its potential for clinical intervention. Overall, our results demonstrate that targeting TLR4 simultaneously curtails pathogenic T-cell differentiation and local neuroinflammation, establishing TLR4 as a dual-action therapeutic target for MS.

Read PDF

Similar papers

Open access Sep 2026

AG490 attenuates neuroinflammation in experimental autoimmune encephalomyelitis possible through promoting autophagy

Multiple sclerosis (MS) is an autoimmune inflammatory disorder that affects the central nervous system (CNS) and has been extensively studied in experimental autoimmune encephalomyelitis (EAE) animal models. AG490, which has potent neuroprotective activity, is used to investigate immune disorders associated with the...

Yu-Long Xue, Lu Zhang, Yu Zhao et al. · 0 citations
Open access Oct 2026

Interferon Regulatory Factor 8 Drives Autoimmune Neuroinflammation in Experimental Autoimmune Encephalomyelitis

Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the central nervous system. The interferon regulatory factor (IRF) family comprises transcription factors that regulate immune responses; however, their roles in MS pathogenesis remain unclear. In this study, we investigated whether IRFs are involve...

H. Ojika, K. Kunisawa, M. Tanabe et al. · 0 citations
Open access Oct 2026

Targeting P2Y12 limits TH17 accumulation in the CNS and reduces EAE progression

Findings support P2Y12 as a mechanistically grounded and translationally relevant target in CNS autoimmunity and identify platelet-associated P2Y12 signaling as a functionally relevant amplifier of EAE pathology.

Niklas Huntemann, Lara-Maria Preuth, T. Krug et al. · 0 citations
Open access Oct 2026

Targeting the HPGDS-PGD2 axis to treat Th17 cell-mediated autoimmunity in multiple sclerosis

Th17 cells are central drivers of autoimmune pathology, including multiple sclerosis (MS), yet the endogenous metabolic signals that shape their pathogenic differentiation remain incompletely defined. Prostaglandin D₂ (PGD2) is traditionally viewed as an extracellular mediator in allergic diseases. Here, we identify PG...

Yu-Xin Zhuang, Kawai Lei, Yan Li et al. · 0 citations
Open access Nov 2026

CD40 ligand and IFN-γ induce proinflammatory activity and microglia-mediated neurodegeneration in human stem cell models

The cluster of differentiation 40 (CD40)/CD40 ligand (CD40L) co-stimulatory pathway plays a critical role in the activation and regulation of immune networks involving both adaptive and innate immune cells. Dysregulation of this pathway has been implicated in multiple autoimmune diseases, including multiple sclerosis (...

Gregory S. Wirak, Sean K. Ryan, Anna S. Blazier et al. · 0 citations
Open access Nov 2026

TNFR2 stimulation induces pathological T-cell activation in a Parkinson’s disease mouse model

Dysregulated T-cell responses and neuroinflammation are key contributors to neurodegeneration in Parkinson’s disease (PD). Modulation of regulatory T-cells (Tregs) to restore immune balance has therefore emerged as a potential neuroprotective strategy. In this study, we investigated whether systemic treatment with th...

A. Makhotkina, R. McFleder, Gabriela Farias Gubert et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.